KROS has 36-month beta value of 1.43. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for KROS is 30.96M, and currently, short sellers hold a 9.77% ratio of that float. The average trading volume of KROS on January 10, 2025 was 897.80K shares.
KROS) stock’s latest price update
Keros Therapeutics Inc (NASDAQ: KROS) has experienced a decline in its stock price by -3.02 compared to its previous closing price of 14.89. However, the company has seen a fall of -9.30% in its stock price over the last five trading days. accesswire.com reported 2025-01-10 that NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
KROS’s Market Performance
KROS’s stock has fallen by -9.30% in the past week, with a monthly drop of -78.49% and a quarterly drop of -75.09%. The volatility ratio for the week is 5.67% while the volatility levels for the last 30 days are 7.39% for Keros Therapeutics Inc The simple moving average for the past 20 days is -25.14% for KROS’s stock, with a -71.58% simple moving average for the past 200 days.
Analysts’ Opinion of KROS
Many brokerage firms have already submitted their reports for KROS stocks, with Oppenheimer repeating the rating for KROS by listing it as a “Outperform.” The predicted price for KROS in the upcoming period, according to Oppenheimer is $63 based on the research report published on December 16, 2024 of the previous year 2024.
H.C. Wainwright gave a rating of “Buy” to KROS, setting the target price at $47 in the report published on December 13th of the previous year.
KROS Trading at -67.44% from the 50-Day Moving Average
After a stumble in the market that brought KROS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.22% of loss for the given period.
Volatility was left at 7.39%, however, over the last 30 days, the volatility rate increased by 5.67%, as shares sank -78.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -76.49% lower at present.
During the last 5 trading sessions, KROS fell by -10.30%, which changed the moving average for the period of 200-days by -78.45% in comparison to the 20-day moving average, which settled at $19.28. In addition, Keros Therapeutics Inc saw -8.78% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KROS starting from GORDON CARL L, who sale 250,000 shares at the price of $44.01 back on Aug 13 ’24. After this action, GORDON CARL L now owns 119,522 shares of Keros Therapeutics Inc, valued at $11,002,500 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of Keros Therapeutics Inc, sale 250,000 shares at $44.01 during a trade that took place back on Aug 13 ’24, which means that ORBIMED ADVISORS LLC is holding 119,522 shares at $11,002,500 based on the most recent closing price.
Stock Fundamentals for KROS
Current profitability levels for the company are sitting at:
- -313.42 for the present operating margin
- -0.27 for the gross margin
The net margin for Keros Therapeutics Inc stands at -278.91. The total capital return value is set at -0.37. Equity return is now at value -43.82, with -40.10 for asset returns.
Currently, EBITDA for the company is -152.18 million with net debt to EBITDA at 2.6. When we switch over and look at the enterprise to sales, we see a ratio of 105.48. The receivables turnover for the company is 0.34for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.03.
Conclusion
To put it simply, Keros Therapeutics Inc (KROS) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
